Jiangsu wuzhong(600200)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 611,782,589.11, representing a year-on-year increase of 37.69%[5] - The net profit attributable to shareholders of the listed company reached CNY 28,152,696.06, a significant increase of 269.61% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,984,226.17, up by 67.86% year-on-year[5] - The company's basic earnings per share for Q1 2023 was CNY 0.040, an increase of 259.29% year-on-year[5] - Net profit for Q1 2023 was RMB 27,581,716.49, compared to RMB 7,016,937.24 in Q1 2022, reflecting a significant increase of approximately 292.5%[19] - The total comprehensive income for Q1 2023 was ¥27,357,334.45, up from ¥7,160,392.95 in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.04, compared to ¥0.01 in Q1 2022, indicating improved profitability[20] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 4,014,492,239.99, reflecting a 2.68% increase from the end of the previous year[6] - The company's total assets as of March 31, 2023, amounted to RMB 4,014,492,239.99, compared to RMB 3,909,731,794.92 at the end of 2022, showing a growth of about 2.7%[16] - Current assets totaled RMB 2,833,932,137.70 as of March 31, 2023, an increase from RMB 2,729,547,553.76 at the end of 2022, representing a growth of approximately 3.8%[14] - Current liabilities increased to RMB 1,965,843,729.82 as of March 31, 2023, from RMB 1,855,556,809.51 at the end of 2022, indicating a rise of about 5.9%[16] - Long-term liabilities decreased to RMB 194,415,344.80 as of March 31, 2023, down from RMB 230,600,842.08 at the end of 2022, reflecting a decline of approximately 15.7%[16] - Total liabilities reached approximately $2.09 billion, with current liabilities at $1.86 billion and non-current liabilities at $230.6 million[27] - Shareholders' equity totaled approximately $1.82 billion, with a significant portion being capital reserves of $1.40 billion[28] Cash Flow - The net cash flow from operating activities was negative at CNY -80,312,170.27, a decline of 284.20% compared to the previous year[5][8] - Cash inflows from operating activities totaled ¥1,861,212,711.77 in Q1 2023, compared to ¥1,538,319,753.00 in Q1 2022, reflecting a growth of approximately 20.9%[22] - The net cash flow from operating activities was negative at -¥80,312,170.27 for Q1 2023, a decline from a positive ¥43,601,145.05 in Q1 2022[22] - Cash inflows from investment activities were ¥225,751,257.64 in Q1 2023, significantly higher than ¥86,880,669.00 in Q1 2022[23] - The net cash flow from financing activities for Q1 2023 was ¥148,902,129.12, compared to ¥123,207,093.37 in Q1 2022, showing an increase of approximately 20.9%[23] - The company reported a total cash inflow from financing activities of ¥696,259,829.84 in Q1 2023, compared to ¥572,340,828.62 in Q1 2022[23] Investment and Other Income - The company reported a significant increase in investment income of 708.20%, attributed to the transfer of equity in Changzheng Xinkai[7] - The company reported a significant increase in investment income, reaching RMB 23,655,227.13 in Q1 2023, compared to RMB 2,926,920.16 in Q1 2022, indicating a growth of approximately 707.5%[19] - The company has a long-term investment in equity amounting to approximately $426 million, showcasing its commitment to strategic investments[26] Other Financial Metrics - The weighted average return on equity increased by 1.14 percentage points to 1.55%[5] - The company experienced a 91.19% decrease in other current assets due to the redemption of financial products[7] - The construction of a new pharmaceutical base has led to a 71.35% increase in construction in progress[7] - The company experienced a decrease in other comprehensive income, with a net amount of -¥224,382.04 in Q1 2023, compared to ¥143,455.71 in Q1 2022[20] - The company reported a net loss of approximately $416.54 million, which is a slight improvement from the previous quarter[28] - The total amount of short-term borrowings was approximately $1.37 billion, indicating reliance on external financing[27] - The company has a deferred tax asset of approximately $2.75 million, which may provide future tax benefits[26]